Development of resistance to chemotherapy in NSCLC is accompanied by a decrease in the expression of Fas and FasL (Okouoyo et al., 2004), whereas upregulation of Fas expression can reverse the DDP resistance of human small-cell lung cancer and ovarian cancer (Wu et al., 2010; Yang et al., 2015). The gene discussed is FAS; the disease is non-small cell lung carcinoma.